Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status
Revista de Neurología · 26.06.2026 · 81 (6)
DOI: 10.31083/rn50142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista de Neurología, online erschienen am 26.06.2026. Verfasst von Siyu Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College of Hangzhou Normal University, 310014 Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Immunotherapy, Autoantibodies. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Traditional Chinese Medicine Science and Technology of Zhejiang Province, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Background:Ocular myasthenia gravis (OMG) is an autoimmune disorder characterized by weakness of the extraocular muscles. This study was developed to investigate the relationship between immunotherapy efficacy and OMG generalization as a function of antibody status, and to explore the efficacy of different immunotherapies in preventing OMG generalization.Methods:This retrospective study included 60 patients admitted to our hospital with initial OMG who were followed for more than two years. Time to generalization was calculated from symptom onset. The proportional hazards assumption was tested using time-dependent covariates, employing Cox regression and Kaplan-Meier analyses to analyze associations for this patient cohort.Results:Among the 60 patients (28 converted OMG; 32 pure OMG), the median time to generalization was 52 months (interquartile range (IQR): 16–117). Antibody positivity was an independent risk factor for generalization (hazard ratio (HR) = 3.89, 95% confidence interval [CI]: 1.26–12.01, p = 0.018). In antibody-positive patients, immunotherapy significantly reduced generalization risk (HR = 0.17, 95% CI: 0.04–0.62, p = 0.008). Conclusion:The time from OMG onset to generalization can be prolonged. While antibody positivity was independently associated with generalization risk in this study cohort, immunotherapy was linked to a time-stable reduction in this risk among antibody-positive patients. These findings provide a preliminary basis for antibody-status-based individualized treatment in OMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College of Hangzhou Normal University, 310014 Hangzhou, Zhejiang, China.
- Center for Pain Management Department, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China.
- Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 310016 Hangzhou, Zhejiang, China.
- Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), 310014 Hangzhou, Zhejiang, China.
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Traditional Chinese Medicine Science and Technology of Zhejiang Province
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Xie, S., Guo, R., Jin, B., Guo, W., Cheng, Y., Song, W., Li, C., Zhang, M., & Wang, Y. (2026). Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status. Revista de Neurología, 81(6). https://doi.org/10.31083/rn50142
Vancouver
Xie S, Guo R, Jin B, Guo W, Cheng Y, Song W, et al. Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status. Revista de Neurología. 2026;81(6). doi:10.31083/rn50142
BibTeX
@article{Xie2026,
author = {Xie, Siyu and Guo, Ran and Jin, Bo and Guo, Wenting and Cheng, Yifan and Song, Wenli and Li, Chunrong and Zhang, Manman and Wang, Yiqi},
title = {Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status},
journal = {Revista de Neurología},
year = {2026},
volume = {81},
number = {6},
doi = {10.31083/rn50142}
}
EUVIMED